Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
US7622458B2 · kind B2 · utility
15Cited by
13References
26Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 15, 2004 |
| Grant date | Nov 24, 2009 |
| Priority date | — |
| Expiry date | Nov 15, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.